Trial Profile

A multi-center Phase 2 study of neoadjuvant immunotherapy in combination with the anti-GDF-15 antibody visugromab (CTL-002) for the treatment of muscle invasive bladder cancer

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2025 According to a CatalYm media release, the data from this trial was presented today by the trials Principal Investigator, Prof. Dr. Andrea Necchi, as an oral late-breaker at the ESMO Congress 2025
17 Oct 2025 Results published in the CatalYm Media Release
22 Sep 2025 According to a CatalYm media release, today announced upcoming oral presentations highlighting data from this trial to be presented at the European Society of Medical Oncology (ESMO) Congress, being held October 17th-21st, 2025, in Berlin, Germany.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com